1.
|
9 p, 1.2 MB |
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
/
Tejedor Vaquero, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
de Campos-Mata, Leire (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ramada, José María (CIBER de Epidemiología Y Salud Pública) ;
Díaz, Pilar (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Navarro-Barriuso, Juan (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ribas-Llaurado, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Rodrigo Melero, Natalia (Centre de Regulació Genòmica) ;
Carolis, Carlo (Universitat Pompeu Fabra) ;
Cerutti, Andrea (Institució Catalana de Recerca i Estudis Avançats) ;
Gimeno Martínez, Ramón (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Magri, Giuliana (Institut Hospital del Mar d'Investigacions Mèdiques)
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. [...]
2021 - 10.3389/fimmu.2021.737083
Frontiers in immunology, Vol. 12 (September 2021) , art. 737083
|
|
2.
|
|
3.
|
13 p, 3.3 MB |
Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Naranjo-Gómez, Mar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sánchez, Alex (Universitat de Barcelona. Departament d'Estadística) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Tolerogenic dendritic cell (tolDC)-based therapies have become a promising approach for the treatment of autoimmune diseases by their potential ability to restore immune tolerance in an antigen-specific manner. [...]
2018 - 10.1038/s41598-018-33248-7
Scientific reports, Vol. 8 (october 2018)
|
|
4.
|
14 p, 1.3 MB |
Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4 + Cells Towards a Functional Hyporesponsiveness
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. [...]
2021 - 10.3389/fimmu.2020.599623
Frontiers in immunology, Vol. 11 (january 2021)
|
|
5.
|
|
6.
|
11 p, 2.0 MB |
Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment
/
Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Navarro-Barriuso, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quirant, Bibiana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ramo-Tello, Cristina (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing-remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. [...]
2019 - 10.1111/cns.13142
CNS neuroscience & therapeutics, Vol. 25 (2019) , p. 995-1005
|
|
7.
|
11 p, 2.0 MB |
Ethyl Pyruvate Induces Tolerogenic Dendritic Cells
/
Djedovic, Neda (University of Belgrade. Department of Immunology) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Jevtić, Bojan (University of Belgrade. Department of Immunology) ;
Navarro-Barriuso, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Saksida, Tamara (University of Belgrade. Department of Immunology) ;
Martínez-Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Miljković, Ðorđe (University of Belgrade. Department of Immunology)
Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. [...]
2019 - 10.3389/fimmu.2019.00157
Frontiers in immunology, Vol. 10 (February 2019) , art. 157
|
|
8.
|
14 p, 1.9 MB |
MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ardiaca-Martínez, Alicia (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Presas-Rodríguez, Silvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Ten Brinke, Anja (Amsterdam UMC. University Medical Center) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The administration of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases, such as multiple sclerosis (MS). Specifically, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most widely studied approaches, as it has evidenced significant immune regulatory properties, both in vitro and in vivo. [...]
2019 - 10.3389/fimmu.2019.01251
Frontiers in immunology, Vol. 10 (June 2019) , art. 1251
|
|
9.
|
20 p, 3.2 MB |
Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA
/
Derdelinckx, Judith (University Hospital Antwerp (Bèlgica)) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
De Laere, Maxime (University of Antwerp. Laboratory of Experimental Hematology) ;
Lee, Wai-Ping (University Hospital Antwerp (Bèlgica)) ;
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Wens, Inez (University of Antwerp. Laboratory of Experimental Hematology) ;
Nkansah, Irene (University of Antwerp. Laboratory of Experimental Hematology) ;
Daans, Jasmijn (University of Antwerp. Laboratory of Experimental Hematology) ;
De Reu, Hans (University of Antwerp. Laboratory of Experimental Hematology) ;
Jolanta Keliris, Aneta (University of Antwerp. Bio-Imaging Lab) ;
Van Audekerke, Johan (University of Antwerp. Bio-Imaging Lab) ;
Vanreusel, Verdi (University of Antwerp. Bio-Imaging Lab) ;
Pieters, Zoë (University of Antwerp. Laboratory of Experimental Hematology) ;
Van Der Linden, Annemie (University of Antwerp. Bio-Imaging Lab) ;
Verhoye, Maraleen (University of Antwerp. Bio-Imaging Lab) ;
Molenberghs, Geert (L-BioStat. I-BioStat. KU Leuven) ;
Hens, Niel (University of Antwerp. Centre for Health Economics Research and Modelling Infectious Diseases) ;
Goossens, Herman (University of Antwerp. Laboratory of Medical Microbiology) ;
Willekens, Barbara (University Hospital Antwerp (Bèlgica)) ;
Cras, Patrick (University of Antwerp. Born Bunge Institute) ;
Ponsaerts, Peter (University of Antwerp. Laboratory of Experimental Hematology) ;
Berneman, Zwi (University Hospital Antwerp (Bèlgica)) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cools, Nathalie (University Hospital Antwerp (Bèlgica))
Background: Although effective in reducing relapse rate and delaying progression, current therapies for multiple sclerosis (MS) do not completely halt disease progression. T cell autoimmunity to myelin antigens is considered one of the main mechanisms driving MS. [...]
2019 - 10.1186/s12974-019-1541-1
Journal of neuroinflammation, Vol. 16 (August 2019) , art. 167
|
|
10.
|
11 p, 861.1 KB |
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS) : A harmonised study protocol for two phase i clinical trials comparing intradermal and intranodal cell administration
/
Willekens, Barbara (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Presas-Rodríguez, Silvia (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Derdelinckx, Judith (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Lee, Wai-Ping (University Hospital Antwerp (Bèlgica)) ;
Nijs, Griet (University Hospital Antwerp (Bèlgica)) ;
De Laere, Maxime (University of Antwerp. Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Wens, Inez (University of Antwerp . Laboratory of Experimental Hematology. Vaccine and Infectious Disease Institute) ;
Cras, Patrick (University Hospital Antwerp (Bèlgica)) ;
Parizel, Paul (University Hospital Antwerp (Bèlgica)) ;
Van Hecke, Wim (Icometrix NV) ;
Ribbens, Annemie (Icometrix NV) ;
Billiet, Thibo (Icometrix NV) ;
Adams, Geert (C-Clear Partners) ;
Couttenye, Marie-Madeleine (University Hospital Antwerp (Bèlgica)) ;
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Lopez-Diaz De Cerio, Ascensión (Clínica Universidad de Navarra) ;
Inogés, Susana (Clínica Universidad de Navarra) ;
Prosper, Felipe (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Kip, Anke (Lygature Utrecht) ;
Verheij, Herman (Lygature Utrecht) ;
Gross, Catharina C. (University of Munster. Department of Neurology) ;
Wiendl, Heinz (University of Munster. Department of Neurology) ;
Van Ham, Marieke (University of Amsterdam. Academic Medical Centre-AMC) ;
Ten Brinke, Anja (University of Amsterdam. Academic Medical Centre-AMC) ;
Barriocanal, Ana María (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Massuet-Vilamajó, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hens, Niel (University of Antwerp. Centre for Health Economic Research and Modelling Infectious Diseases) ;
Berneman, Zwi (University of Antwerp. Center for Cell Therapy and Regenerative Medicine) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cools, Nathalie (University Hospital Antwerp (Bèlgica)) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Introduction Based on the advances in the treatment of multiple sclerosis (MS), currently available disease-modifying treatments (DMT) have positively influenced the disease course of MS. However, the efficacy of DMT is highly variable and increasing treatment efficacy comes with a more severe risk profile. [...]
2019 - 10.1136/bmjopen-2019-030309
BMJ open, Vol. 9, Issue 9 (July 2019) , art. e030309
|
|